Clinical trials: Prostate Cancer, Castration Resistant
Prostate Cancer
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
The purpose of this study is to learn about the safety of TALZENNA in patients with BRCA mutation-positive metastatic castration-resistant prostate cancer. BRCA mutation positive means any changes to the BRCA gene.
- Trial name
- NCT06733337
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC.
- Trial name
- NCT02262910
- Testing
- ES414
- Where
- 7 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Aptevo Therapeutics
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that…
- Trial name
- NCT06288113
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer.
- Trial name
- NCT01543776
- Testing
- abiraterone acetate
- Where
- 6 sites in United States, Singapore
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Prostate Cancer
Testosterone in Castration-Resistant Prostate Cancer
Primary Objective: 1. To assess the prostate-specific antigen (PSA)-response (50% decline) to Testosterone Replacement Therapy (TRT) in men with "intermediate and good-risk" Castration-Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00577980
- Testing
- Testosterone
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer
Prostate Cancer
Metformin in Castration-Resistant Prostate Cancer
Metformin is a medication that is prescribed for people with diabetes to help the body respond better to its own insulin and decrease sugar production by the liver.
- Trial name
- NCT01215032
- Testing
- Metformin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Metastatic Castration-Resistant Prostate Cancer
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone.
- Trial name
- NCT01650194
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer
Liquid Biopsy Under PSMA Radioligand Therapy
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic…
- Trial name
- LOOPS (NCT07118436)
- Where
- 3 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Wuerzburg University Hospital
Castration-resistant Prostate Cancer
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
- Trial name
- NCT02669771
- Testing
- enzalutamide
- Where
- 47 sites in Japan
- Volunteers
- 1,018 people
- Sponsor
- Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer (mCRPC)
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA
- Trial name
- WB-LuPSMA (NCT05208229)
- Testing
- WB-MRI
- Where
- 2 sites in Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05398302
- Testing
- Image Guided Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Prostate Carcinoma
Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223…
- Trial name
- NCT03011749
- Testing
- FLT PET/CT
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06145633
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Hormone Refractory Prostate Cancer
Radiotherapy vs Observation for CRPC
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
- Trial name
- NCT01590498
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhengzhou University
Castration-resistant Prostate Cancer
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with…
- Trial name
- RAPIT (NCT04232761)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the…
- Trial name
- NCT04225910
- Testing
- 225Ac-PSMA
- Volunteers
- 20 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine